TheraRadar
← Back
Data updated: Jun 28, 2026

CARDINAL HLTH 414

Generics
Pharmaceuticals

CARDINAL HLTH 414 is a generic drug manufacturer with 2 FDA-approved products.

2013
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

CARDINAL HLTH 414's Key Drugs

CARDINAL HLTH 414's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CARDINAL HLTH 414's Recent FDA Approvals

New NDA/BLA approvals for CARDINAL HLTH 414 over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CARDINAL HLTH 414's Therapeutic Areas

Disease areas where CARDINAL HLTH 414 has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

CARDINAL HLTH 414 Pipeline Snapshot

Active clinical trials for CARDINAL HLTH 414 across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling